Charles River Laboratories International (NYSE:CRL) Stock: Insider Shannon Parisotto Sells 2,156 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 2,156 shares of the business’s stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total transaction of $742,547.96. Following the sale, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,655,578.87. The trade was a 30.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock traded up $5.42 during trading hours on Friday, reaching $345.08. The company’s stock had a trading volume of 822,279 shares, compared to its average volume of 947,095. The company’s 50 day simple moving average is $293.05 and its 200 day simple moving average is $232.43. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a one year low of $146.20 and a one year high of $351.21. The stock has a market cap of $16.47 billion, a P/E ratio of -71.15, a price-to-earnings-growth ratio of 3.22 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same period in the previous year, the business posted $3.12 EPS. The company’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Jefferies Financial Group upped their target price on Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a report on Monday, September 28th. Robert W. Baird raised their price target on Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a report on Friday, September 25th. Piper Sandler set a $300.00 price objective on Charles River Laboratories International in a research report on Monday, August 10th. Deutsche Bank Aktiengesellschaft boosted their price objective on Charles River Laboratories International from $300.00 to $320.00 and gave the company a “buy” rating in a research report on Friday, September 25th. Finally, CLSA downgraded Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research note on Monday, July 20th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International has an average rating of “Moderate Buy” and an average target price of $302.33.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRL. Physician Wealth Advisors Inc. raised its stake in shares of Charles River Laboratories International by 127.9% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock worth $29,000 after buying an additional 55 shares in the last quarter. Continuum Advisory LLC bought a new position in Charles River Laboratories International during the second quarter valued at about $30,000. IFP Advisors Inc boosted its stake in Charles River Laboratories International by 182.8% during the third quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock valued at $48,000 after buying an additional 106 shares in the last quarter. Compass Wealth Management LLC acquired a new position in Charles River Laboratories International during the third quarter worth about $69,000. Finally, Activest Wealth Management grew its holdings in Charles River Laboratories International by 25.9% during the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after acquiring an additional 57 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.